Content Navigation
( All
None )
| Target and Pathway |
Top |
| Target(s) |
Mammalian target of rapamycin complex 1 (mTORC1) |
Target Info
|
Inhibitor |
[3] |
| Serine/threonine-protein kinase mTOR (mTOR) |
Target Info
|
Inhibitor |
[4] |
| Target of rapamycin complex 2 MAPKAP1 (MTORC2) |
Target Info
|
Inhibitor |
[3] |
| References |
Top |
| REF 1 |
URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7699).
|
| REF 2 |
ClinicalTrials.gov (NCT01793636) A Study Comparing AZD2014 vs Everolimus in Patients With Metastatic Renal Cancer. U.S. National Institutes of Health.
|
| REF 3 |
Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
|
| REF 4 |
Dramatic suppression of colorectal cancer cell growth by the dual mTORC1 and mTORC2 inhibitor AZD-2014. Biochem Biophys Res Commun. 2014 Jan 10;443(2):406-12.
|
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.
